Cowen & Co. analyst Marc Frahm maintained a Hold rating on Merrimack Pharmaceuticals (MACK) today. The company’s shares opened today at $4.75, close to its 52-week low of $3.34.
According to TipRanks.com, Frahm is a 1-star analyst with an average return of -9.0% and a 31.6% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Gritstone Oncology Inc, and Blueprint Medicines.
Merrimack Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $4.
See today’s analyst top recommended stocks >>
The company has a one-year high of $12.54 and a one-year low of $3.34. Currently, Merrimack Pharmaceuticals has an average volume of 99.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath and Ulrik B.
